A randomized controlled trial of trypsin to treat brown recluse spider bites in Guinea pigs.
Brown recluse spider bites result in necrotic skin lesions for which there is no known antidote. Since venom toxins are proteins, a proteolytic enzyme like trypsin might be effective in reducing toxicity. The aim of this study was to conduct a randomized controlled trial of trypsin to treat brown recluse spider bites in guinea pigs. Subjects were 18 female guinea pigs. Anesthesia for injections was inhaled isoflurane. Analgesia was 0.05 mg/kg of buprenorphine twice a day as needed. Intervention was intradermal injection of 30 μg of brown recluse venom (Spider Pharm, Yarnell, AZ). Immediately after envenomation, subjects were randomized to two groups of nine: trypsin 10 μg in 1 mL normal saline and 1 mL of normal saline. The primary outcome was lesion area over a 10-day time period. Statistical analysis was performed with repeated measures ANOVA. Mean lesion area was smaller but not statistically different in the placebo group. Maximum lesion size occurred at day 4 in both groups, when lesion area was 76.1 ± 108.2 mm(2) in the placebo group and 149.7 ± 127.3 mm(2) in the treatment group. P value was 0.15 for placebo vs. treatment. This study did not establish a role for trypsin as a treatment for brown recluse spider bites in a guinea pig model.
Department of Emergency Medicine, Brody School of Medicine, East Carolina University, 600 Moye Boulevard, Room 3ED311, Greenville, NC, 27834, USA.
Wyman W
WW
Cabaniss
Sean
S
Bush
Dorcas P
DP
O'Rourke
Paul F
PF
Fletcher
Kori L
KL
Brewer
Kvin
K
Lertpiriyapong
Mohan
M
Punja
Susan N
SN
Miller
William J
WJ
Meggs
D000818:Animals; D063287:Brown Recluse Spider; D005260:Female; D006168:Guinea Pigs; D001098:Spider Bites / Q000188:drug therapy*; D014357:Trypsin / Q000627:therapeutic use*
D014357:Trypsin